Author:
Alshuraim Renad,Altuwayjiri Abdullah,Albanayan Nurah,Orfali Razan,Alsaleem Badr,Mathkour Mujeeb
Reference7 articles.
1. Shaffer D, Butterfield M, Pamer C, Mackey AC Tardive dyskinesia risks and metoclopramide use before and after US market withdrawal of cisapride. J Am Pharm Assoc 2004;44:661-5.
2. Lee A, Kuo B Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab 2010;5:653-62.
3. Tianyi F-L, Agbor VN, Njim T Metoclopramide Induced Acute Dystonic Reaction: A Case Report . BMC Res Notes 2017;10:1-3.
4. 017862s063lbl.pdf [Internet]. [cited 2021 Sep 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017862s063lbl.pdf. [Last accessed on 06 Sep 2021].
5. Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, Díez-Fernández A, Notario-Pacheco B Risk of extrapyramidal side effects comparing continuous vs bolus intravenous metoclopramide administration: A systematic review and meta-analysis of randomised controlled trials. J Clin Nurs 2015;24:3638-46.